Opioid Addiction Treatment: Evidence-Based Options

What can opioid addiction treatment include?

The core of opioid treatment is medication. Three are FDA approved: buprenorphine and methadone, which relieve withdrawal and craving and cut overdose deaths substantially, and naltrexone, which blocks opioids. Around the medication: individual therapy, treatment for the depression, trauma, or pain that often accompany opioid use, practical help with the things that break attendance (transport, housing, work), and naloxone in the home. NIDA's principles are plain about this: medication combined with behavioral treatment is the standard of care, and treatment that omits medication is not evidence-based for opioid use disorder.

Care should also respond to pain, infectious disease risk, pregnancy, sleep, trauma, depression, anxiety, legal concerns, transportation, and the person's ability to attend treatment. Opioid use disorder is treatable, and remaining connected to effective care matters. See NIDA's medications for opioid use disorder overview.

For example, someone working variable shifts needs appointment times and medication access that fit that pattern. A person traveling between services needs a receiving provider and records handoff before departure. These practical arrangements determine whether the treatment plan is usable, particularly when medication and counseling are delivered by different organizations.

Which medications are used to treat opioid addiction?

The FDA has approved methadone, buprenorphine, and naltrexone for opioid use disorder. Each works differently and has different starting requirements, delivery methods, access rules, benefits, and risks. A qualified prescriber should determine which option fits the person's medical history, current opioid use, treatment goals, and ability to remain in care.

In practice: buprenorphine can be prescribed by a practitioner with the required DEA authority and permission under applicable state law, is picked up at a pharmacy, and comes as daily films or tablets or as monthly and weekly injections. Methadone for opioid use disorder is dispensed only through certified opioid treatment programs, with supervised visits and take-home arrangements set by the opioid treatment program according to clinical needs and applicable rules. Naltrexone requires the person to be fully withdrawn first, typically seven to ten days opioid-free, and is usually given as a monthly injection; it suits people who cannot or do not want to take an opioid medication. Medications for opioid use disorder compares the three in detail.

The care plan also identifies where the medicine comes from, how often appointments occur, and who handles follow-up. These access arrangements affect the weekly routine as much as the choice of formulation.

Medication decisions belong with a prescriber. See FDA information about medications for opioid use disorder.

Swipe sideways to see all columns.

What role does behavioral treatment play in opioid recovery?

Behavioral interventions address motivation, coping, relationships, routines, and related mental health needs. Individual, family, and group delivery are different options. Counseling participation must not become an unnecessary barrier to appropriate opioid medication.

Transport, housing, childcare, work, cost, and communication affect access to care. A usable plan identifies the barriers disrupting attendance and the arrangements needed to address them.

A scheduled family appointment or a regular transport arrangement addresses a different need from the prescribing visit, while supporting continued attendance.

Is opioid detox enough by itself?

No. Detox manages withdrawal, while ongoing opioid use disorder treatment addresses continued recovery and lowers overdose risk. Reduced tolerance after a period without opioids increases the danger if use resumes. CDC recommends ongoing medication treatment rather than detoxification alone. The discharge plan connects the person with a medication provider, naloxone access, and the next appointment. Transport, pharmacy arrangements, and a working contact number turn those recommendations into services the person can actually reach after leaving withdrawal care.

The numbers behind that answer: after a week or two without opioids, tolerance drops, and the dose a person used before can now cause a fatal overdose. Studies of people leaving detox and incarceration without medication show overdose deaths concentrated in the first two weeks. That is why the standard of care is to start buprenorphine or methadone during or immediately after withdrawal rather than to "complete detox" and start therapy. If detox alone is the plan, naloxone in the home is the minimum, and it is not enough.

Why should naloxone be part of an opioid treatment plan?

Naloxone reverses opioid overdose when administered in time. Patients and likely responders need access, recognition of overdose signs, and instructions for the product. Suspected overdose requires 911 and continued attention until emergency help arrives.

Call 911 if someone may be overdosing. Give an available opioid overdose reversal medication according to its instructions and provide rescue breathing or CPR if trained and needed. See SAMHSA's opioid overdose reversal information.

The transition plan includes where the product will be kept and which household members know where to find it.

How long does opioid addiction treatment last?

Medication for opioid use disorder is best thought of like medication for any chronic condition: many people stay on buprenorphine or methadone for years, and outcomes are better the longer they do. Stopping early, especially in the first year, is associated with return to use and overdose. Therapy is usually most intensive in the first three months and tapers to monthly or as needed. A 30-day residential stay is one phase of opioid treatment, which may continue after discharge.

Medication continues for as long as it remains beneficial and clinically appropriate. The patient and clinician review response, safety, access, and preferences; a short residential deadline does not determine treatment duration.

A change of residence, insurer, or prescriber is a coordination task within that continuing treatment. The next appointment and medication arrangement should be settled before the previous service ends, with relevant records reaching the receiving provider.

How should the parts of opioid treatment connect?

Opioid treatment connects appropriate medication, behavioral support, overdose prevention, medical care, and continuing access. Transitions between providers must account for prescribing and dispensing responsibilities.

Protect immediate safety

Naloxone available now, overdose signs explained to the people around the person, any medical or psychiatric emergency handled first, and safe transport to the first appointment.

Complete a substance and health assessment

Which opioids, how much, by what route, for how long; other substances, especially benzodiazepines and alcohol, which multiply overdose risk; overdose history; pregnancy; infections associated with injection; pain; mental health; and current medications.

Offer medication-inclusive care

Buprenorphine, methadone, or naltrexone explained as options, with a prescriber who can start one within days, not a referral list.

Match behavioral and practical support

Individual therapy for the patterns and the conditions underneath them; help with transport, housing, work, and childcare, because those are what end treatment in practice.

Select the necessary level of care

Most people with opioid use disorder can be treated as outpatients with medication. Residential care is for people who cannot stop using at home, have unstable housing, or need medical or psychiatric stabilization.

Protect retention and transition

A prescriber who continues after any program ends, medication in hand at discharge, appointments booked, and a rule that a missed appointment triggers a call, not a discharge.

Fentanyl addiction treatment covers what changes when fentanyl is involved; medications for opioid use disorder compares the three medications.

Can opioid addiction treatment be outpatient or residential?

Yes. Opioid use disorder treatment can occur through outpatient medical practices, certified opioid treatment programs, intensive outpatient care, residential programs, hospitals, and coordinated private settings. The correct level of care depends on medical and psychiatric needs, current safety, other substances, environment, stability, and available support.

For someone already stable in outpatient treatment, a move to a private residence still needs coordination with the existing medication service. A more intensive setting adds staffing and daily structure; the treatment plan identifies which services continue through the same provider and which transfer.

Routine outpatient methadone treatment for opioid use disorder is delivered through certified opioid treatment programs, with limited medical-setting exceptions. Qualified clinicians prescribe buprenorphine in other authorized settings. MOUD access explains the distinction.

Medication and counseling while living at home

Outpatient care can include buprenorphine from a prescriber, or methadone through an opioid treatment program, plus individual therapy. Appointments may begin frequently and become less frequent as the plan allows; methadone take-home arrangements depend on the program and the person's circumstances. The home situation, ability to attend appointments, and medical and psychiatric needs help determine whether this setting provides enough support.

Structured living with treatment

Residential care for people who cannot stop using where they live, with medication started or continued on site or through daily transport to an opioid treatment program. Confirm the program supports medication; some still do not, and that is disqualifying for opioid treatment.

Care for serious medical or psychiatric needs

Hospital or medically managed care when withdrawal is complicated by other substances, when there is a serious infection or pregnancy complication, or when psychiatric symptoms make outpatient care unsafe. Medication is started there and continued after.

What should you ask an opioid treatment program?

The essential questions concern medication options, access delays, overdose prevention, clinical support, and continuity after the initial service. Program policies require scrutiny when they obstruct indicated medication without an individualized medical reason.

Which medications are available directly or through coordination?

Ask about prescribers, opioid treatment programs, pharmacies, starting procedures, and continuity.

How does the program respond to fentanyl and multiple substances?

Review assessment, overdose prevention, medical capability, testing, and transfer criteria.

What happens after resumed use or a missed appointment?

Look for safety, reassessment, medication continuity, and re-engagement rather than automatic abandonment.

How are privacy and communication handled?

Review records, consent, billing, family contact, work needs, portals, voicemail, and emergencies.

What continuing care is confirmed before discharge?

Identify medication, prescriber, appointments, naloxone, housing, transport, support, and response plans.

From the first conversation to the next step

The first discussion should include current opioid treatment and any existing prescribing arrangements. The clinical conversation then establishes the care setting and how medication access will continue. Before a transition, identify the receiving service and next appointment. Delays in coordination or access are reasons to clarify the handoff rather than assume a new program has already arranged it.

The person also leaves each conversation knowing the next date, location, and contact method, rather than an instruction to arrange everything independently.

Keeping opioid medication accessible

Medication access needs to survive a move, a discharge, or a change of coverage. The next prescriber or opioid treatment program, pharmacy arrangements where applicable, and appointment date are concrete parts of the plan. Medication duration is determined with the treating clinician, not by a residential package end date.

Naloxone is an emergency overdose-reversal medicine, not ongoing treatment for opioid use disorder. The patient and people likely to be present need access and instructions. Suspected overdose requires 911 even when naloxone is given.

Questions about opioid addiction treatment

Sources and further reading

• NIDA: Medications for Opioid Use Disorder
• FDA: Information About Medications for Opioid Use Disorder
• CDC: Treatment of Opioid Use Disorder
• SAMHSA TIP 63: Medications for Opioid Use Disorder
• SAMHSA: Opioid Overdose Reversal Medications
• CDC: Naloxone and emergency overdose response
• NIDA: Principles of Drug Addiction Treatment, Third Edition
• CDC: Reverse Opioid Overdose to Prevent Death
• SAMHSA TIP 63: Medications for Opioid Use Disorder
• Santo et al. (2021): Opioid agonist treatment and mortality

Sources checked September 7, 2026